Pharmaceutical company Dienst announced the appointment of Angelo Paci, PharmD, PhD, as program leader in oncology and immuno-oncology. Angelo Paci will report to Walid S. Kamoun, director of oncology research and development. He will also work with Fabien Schmidlin, Director of Translational Medicine, with whom he will have a functional connection.
Angelo Paci’s responsibilities are part of Dienst’s global strategy in oncology, aimed at fighting difficult-to-treat cancers. He will contribute to the excellence of strategic assessments of pharmacokinetics and pharmacodynamics for early drug development in oncology. In particular, he will play a leading role in supporting drug reformulation efforts in pediatric oncology.
“I am very pleased to welcome Angelo Paci, whose scientific expertise in the field of oncology is internationally recognized. He will be instrumental in realizing the group’s oncology and immuno-oncology ambitions,” said Walid S. Kamoun, R&D Oncology Director at Dienst.
“I am delighted that Angelo Paci is joining the Dienst Group. I am convinced that it will make a significant contribution to offering new therapeutic solutions to cancer patients. His solid expertise acquired at Gustave Roussy, the leading center in the fight against cancer in Europe, will also allow us to strengthen the translational medicine approach by optimizing the medical-scientific strategy of our R&D projects “, adds Fabien Schmidlin. , Director of Translational Medicine at Dienst.
Angelo Paci is Professor of Pharmacokinetics and Oncology at the Faculty of Pharmacy at Paris-Saclay University. He is a member of the French Academy of Pharmacy, the American Association for Cancer Research (AACR) and the Pharmacology and Oncology Group of Unicancer France. Angelo Paci, who holds a PhD in Pharmacy from the University of Paris V and a PhD in Therapeutic Chemistry from the Faculty of Pharmacy, was Head of the Pharmacology Department at Cancer Campus Gustave Roussy shortly before joiningServe.
With 20 years of academic and clinical experience focused on oncology, Angelo has led numerous preclinical, translational and clinical projects. For more than 15 years, he has developed a clinical-pharmacological activity dedicated to patients with oncohematological malignancies, including therapeutic drug monitoring and pharmacokinetic studies of anticancer drugs and metabolic biomarkers.
Angelo Paci is the author of more than 140 scientific publications (including articles in Cancer Discovery, Nature Comm or Journal of Clinical Oncology) and holds six patents.
“I am delighted to joinServing and look forward to collaborating with an international team of experts working with and for patients to provide innovative therapeutic solutions in the fields of oncology and immuno-oncology,” says Angelo Paci.
Source and image: server